Cipla Ltd Company Overview

Cipla is engaged in manufacturing prescription drugs, animal products, OTC (over-thecounter) products, bulk drugs, flavors and fragrances, and agrochemicals. Additionally, it offers technology services such as consulting services, project appraisal, engineering, plant supply, training, operational management and support services. The company primarily operates in India, where it is headquartered in Mumbai. Turnover (INR Mn): 53,595.2

Business Description
Cipla is a pharmaceutical company that develops, manufactures, and sells pharmaceutical products. The company exports raw materials, intermediates, prescription drugs, OTC (overthe-counter) products and veterinary products to over 170 countries. In addition, the company offers technology for products and processes. The company's products include: prescription drugs, animal health care products, OTC products, bulk drugs, flavors and fragrances, and agrochemicals. The prescription drugs include alzheimer`s dementia, amoebicides/antiprotozoals, anabolic steroids, analgesics/antipyretics, anesthetic agents, antacids/antiflatulents, anthelmintics, antiarthritis, anti-inflammatory drugs, anti-TB drugs, and antiacne/antipsoriatic drugs, benign prostatic hyperplasia drugs, cardiovascular agents, cerebral vasodialators, cholestrol reducers/hypolipedemic agents, cough and cold drugs, diuretics, erectile dysfunction therapy, expectorants/cold preparations/mucolytes, eye and ear preparations, gout preparations, haematinic preparation, haemorrhoelogic agents, haemostatics, hormone - related drugs, hormone replacement therapy, immunosuppressants, iron chelators, irritable bowel syndrome, laxatives, motility regulators, multihalers, nasal preparation, nutritional supplements, pregnancy testing kit, respiratory devices, respiratory drugs, saliva supplements, sedative hypnotics, skeletal muscle relaxant, systemic corticosteroids, topical anti-infectives, topical corticosteroids, topical preparations, urinary smooth muscle contractor, urinary smooth muscle relaxants, uterine stimulants, vertigo preparation and wart preparations. The company's animal health care products are provided as animal groups, herbal specialties and therapeutic groups. Its animal group products are active pharmaceutical ingredients, aqua products, disinfectants and sanitizers, equine products, feed and feed additives, general products, herbal products, Pluto's choice dog treats and chews, poultry products, products for companion animals, products for livestock animals, and surgical and equipments. The company offers herbal specialty products and therapeutic group products include: anaesthetics, anthelmintics, anti-inflammatory agents, antibiotic and antiinfective supplements, antibiotics/antibacterials, antibiotics/antibacterials for topical, anticoccidials, antidiarrhoeal fibre supplement, antidiarrhoeals, antidiarrhoeals/anticoccidials, antimicrobials, antiprotozoals, antisedative, antiseptics, antispasmodics, antiulcerant, bronchodilators, counterirritants, rubefacients, dermatological preparations, detoxicant and laxative powder, disinfectants and sanitizers, diuretics, drug for external parasites (ectoparasiticides), drug for tympany and bloat, drugs for blood protozoan diseases, drugs for

congestive heart failure, drugs for treatment of ulcer, ect-endoparasiticides, electrolytes, enzymes, eye/ear preparations, feed supplement, growth promoters, herbal liver protector, herbal specialities, hormonal preparations, intramammary infusion for mastitis, iron preparation, mold inhibitors, nutritional supplements, oestrus inducers, opthalmic preparation, pet accessories, premium range of foods, sedatives, udder care, and vitamins and mineral preparations. Cipla's OTC products are child care, cough, cold's and flu, eye care, food supplements, foot care, hair care, health drinks, life style products, low - calorie sweetener, nutraceuticals and tonics, oral hygiene, others, pain care, probiotics/indigestion, skin care, sports care/muscle building, and vitamins and minerals. The company's bulk drugs include: active pharmaceutical ingredients, and drug intermediates. The active pharmaceutical ingredients are arthritic / rheumatic agents, antibiotics / antibacterial, anticancer drugs, anti-emetics, antifungal, antihelmintics, antihistamines, antimalarials, antiparkinson agents, antiviral, asthma / COPD drugs, cardiovascular drugs, CNS drugs, gastrointestinal drugs, hypoglycaemics, migraine medications, ophthalmic drugs, osteoporosis, urology drugs, and others. Some of the drug intermediates include: albuterol sulfate/ (salbutamol sulphate) and salbutamol, alprazolam, bambuterol hci, bicalutamide, carvedilol, ciclesonide, danazol, doxazosin mesylate, dutasteride, entacapone, etoposide, finasteride, flutamide, gabapentin, imiquimod, leflunomide and others. Cipla's flavours are used in the food and beverages and pharmaceutical industry from fruit juices and medicinal liquids to baked goods and oral hygiene products. The fragrances have a variety of applications ranging from personal care products to laundry detergents and room fresheners. The company's agrochemical products are pesticides.

History
Cipla was formed in 1935 by Khwaja Abdul Hamied as The Chemical, Industrial & Pharmaceutical Laboratories. In 1944, the company bought the premises at Bombay Central and decided to put up a modern pharmaceutical works and laboratory. Cipla's product for hypertension, Serpinoid, was exported to the American Roland Corporation in 1946. The company's Vikhroli factory started manufacturing diosgenin in 1961. The company manufactured ampicillin in 1968. Cipla started Agricultural Research Division at Bangalore, for scientific cultivation of medicinal plants in 1972. The company launched medicinal aerosols for asthma in 1976 and the company's fourth factory started operations at Patalganga, Maharashtra in 1982. Cipla developed anti-cancer drugs, vinblastine and vincristine in collaboration with the National Chemical Laboratory, Pune in 1984. In the following year, the company was approved by US FDA for bulk drug manufacturing facilities.

The company launched etoposide, a breakthrough in cancer chemotherapy, in association with Indian Institute of Chemical Technology in 1991. Cipla's fifth factory started commercial production at Kurkumbh, Maharashtra in 1994. The company launched transparent Rotahaler, the dry powder inhaler device patented by Cipla in India and abroad in 1997. The company set up four manufacturing facilities in Goa, in 2002. In the following year, Cipla launched TIOVA (Tiotropium bromide), a novel inhaled, long-acting anticholinergic bronchodilator that is employed as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). Cipla set up facility for manufacture of formulations at Baddi, Himachal Pradesh, in 2005. In the following year, Cipla received approval from the US Food and Drug Administration for generic AIDS drug nevirapine in the tablet form. In 2006, the company set up a wholly owned subsidiary, Cipla FZE in Dubai. In the same year, Cipla partnered with Japan bio-venture firm LTT Bio-Pharma to develop nanosteroids. The company entered into a development and supply agreement with Drugs for Neglected Diseases Initiative (DNDi), a non-profit organization, for a new anti-malarial combination drug, in 2007. In the same year, Cipla launched Virenza inhalation capsules (zanamivir). Also in the same year, the company developed and launched an estradiol transdermal spray (marketed as EstaSpray). In 2008, the company received product patents for new forms of two drugs: Osemaprazole and Alendronate from the Indian authorities. Cipla secured tentative approval from the US Food and Drug Administration (USFDA) for its tenofovir disoproxil fumarate tablets, in May 2009. In March 2010, the company sold its 'i-pill' contraceptive brand to Piramal Healthcare Limited for INR950 million. The company established a wholly-owned subsidiary, Cipla Singapore, in Singapore to aid logistics and distribution of the company's export business, in May 2010. In the following month, Cipla acquired 40% and 25% stake in two biotech companies, based in India and Hong Kong respectively. In August 2010, Cipla acquired Meditab Specialities (Meditab), which had small and midsized formulation manufacturing facilities at multiple locations. The company launched Pirfenidone in India, under the brand name Pirfenex, for the treatment of Idiopathic Pulmonary Fibrosis (IPF), in October 2010.

Key Products
Cipla is an India based pharmaceutical company. The company's key products include the following:

Products: Prescription drugs Alzheimer`s dementia Amoebicides/antiprotozoals Anabolic steroids Analgesics/antipyretics Anesthetic agents Antacids/antiflatulents Anthelmintics Anti-arthritis Anti-inflammatory drugs Anti-TB drugs Antiacne/antipsoriatic drugs Antiallergic drugs Antibiotics/antibacterials Anticancer drugs Anticoagulant Antithrombotic agents Animal health care products Animal group products Herbal specialty products Therapeutic group products OTC products Child care products Cough, cold and flu products

Eye care products Food supplements Foot care products Hair care products Health drinks Life style products Low - calorie sweetener Nutraceuticals and tonics Oral hygiene products Pain care products Probiotics/indigestion products Skin care products Sports care/muscle building products Vitamins and minerals Bulk drugs Active pharmaceutical ingredients Drug intermediates Flavors and fragrances Agrochemicals Pesticides

Key Employees
Y K Hamied - Chairman and Managing Director M K Hamied - Joint Managing Director S Radhakrishnan - Executive Director and Chief Financial Officer

Key Facts:
Cipla introduces new pain free screening technology for early detection of breast cancer in India - No Touch Breast Scan 30 November 2010 Cipla extends an innovative MotherBaby Pack for preventing mother-to-child transmission of HIV/AIDS 20 October 2010 Cipla launches the worlds first generic Pirfenidone in India, giving hope to sufferers of IPF (Idiopathic Pulmonary Fibrosis) 06 July 2010 Life sciences industry in Asia grew 3.4% in 2009 survey. 23 march 2010 Piramal Healthcare Acquires "i-pill", a Leading Emergency Contraceptive Brand from Cipla 12 November, 2009 Cipla launches generic drug to treat H1N1. Company Address Mumbai Central Mumbai 400 008 Maharashtra IND T: 91 22 2308 2891 F: 91 22 2307 0013